These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33364967)

  • 41. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.
    Mease PJ; Van den Bosch F; Sieper J; Xia Y; Pangan AL; Song IH
    J Rheumatol; 2017 May; 44(5):599-608. PubMed ID: 28298558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index.
    Maksymowych WP; Mallon C; Morrow S; Shojania K; Olszynski WP; Wong RL; Sampalis J; Conner-Spady B
    Ann Rheum Dis; 2009 Jun; 68(6):948-53. PubMed ID: 18524792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
    Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
    World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.
    Kneepkens EL; Wei JC; Nurmohamed MT; Yeo KJ; Chen CY; van der Horst-Bruinsma IE; van der Kleij D; Rispens T; Wolbink G; Krieckaert CL
    Ann Rheum Dis; 2015 Feb; 74(2):396-401. PubMed ID: 24326011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
    Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
    Kimel M; Revicki D; Rao S; Fryback D; Feeny D; Harnam N; Thompson C; Cifaldi M
    Clin Exp Rheumatol; 2011; 29(4):624-32. PubMed ID: 21813060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.
    Maksymowych WP; Strand V; Nash P; Yazici Y; Thom H; Hunger M; Kalyvas C; Gandhi KK; Porter B; Jugl SM
    Eur J Rheumatol; 2018 Dec; 5(4):216-223. PubMed ID: 30388073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
    Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan.
    Kobayashi S; Kashiwagi T; Kimura J
    Mod Rheumatol; 2019 Nov; 29(6):1007-1012. PubMed ID: 30221573
    [No Abstract]   [Full Text] [Related]  

  • 57. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index in Turkish patients with ankylosing spondylitis: relationship with disease activity and quality of life.
    Zahiroglu Y; Ulus Y; Akyol Y; Tander B; Durmus D; Bilgici A; Kuru O
    Int J Rheum Dis; 2014 Feb; 17(2):173-80. PubMed ID: 24576273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Validation of the Italian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) in patients with ankylosing spondylitis].
    Salaffi F; Stancati A; Silvestri A; Carotti M; Grassi W
    Reumatismo; 2005; 57(3):161-73. PubMed ID: 16258600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.